University of Michigan Oncologist Receives Breast Cancer Research Foundation Grant for Work With Tumor Markers
Funding made possible through the support of Eisai Inc.

Woodcliff Lake, NJ, October 25, 2011 - The Breast Cancer Research Foundation (BCRF) announced today that it has awarded a research grant to Daniel F. Hayes, MD, Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, for his work on behalf of the North American Breast Cancer Group (NABCG). The award is funded through a sponsorship from Eisai Inc.

Each year BCRF's Board of Scientific Advisors invites meritorious individuals and groups to submit proposals for support of promising clinical and translational research studies aimed at breast cancer prevention and cure.

"Eisai is honored to support continued research into breast cancer with the hope that one day this research may improve the lives of patients with cancer," said Dr. Takashi Owa, chief scientific officer, Eisai Product Creation Systems and president of the Oncology Product Creation Unit at Eisai Inc.

Dr. Hayes, a professor of internal medicine at the University of Michigan, also leads the NABCG, which conducts prospective randomized clinical trials that have changed practice patterns for patients with breast cancer, especially at the beginning of therapy.

"On behalf of my colleagues at NABCG, I am honored to receive this grant from The Breast Cancer Research Foundation. We are committed through our research to improve personalized cancer care and treatment of patients," said Dr. Hayes. "I am grateful to Eisai for supporting important breast cancer research studies through its generosity to BCRF."

The Correlative Science Committee of the NABCG studies tumor markers and the role they play in determining a breast cancer patient's therapy. NABCG has collected and stored breast cancer tissue from patients who have participated in clinical trials since the early 1990's. The funding for this project enables use of these tissue samples for studies of new or promising tumor markers. These studies are subject to a rigorous review process.

About BCRF
The Breast Cancer Research Foundation® was founded in 1993 by Evelyn H. Lauder as an independent, not-for-profit organization dedicated to funding innovative clinical and translational research. In October 2011, BCRF is awarding $36.5 million to 186 scientists across the United States, Canada, Latin America, Europe, the Middle East, Australia and China. Currently, more than 90 cents of every dollar donated is directed to breast cancer research and awareness programs. With exceptionally low administrative costs, BCRF continues to be one of the most efficient organizations in the country and is designated an "A+" charity by The American Institute of Philanthropy, the only cancer organization to achieve this. For more information about BCRF, visit

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai Oncology is dedicated to discovering, developing and producing innovative oncology therapies that may make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to increase the benefits health care provides. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, vaccines, and biologic agents across various types of cancer. For more information about Eisai, please visit

Type Press Release

Date Released October 25, 2011

Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
* Required Fields